Understanding cannabinoid receptors: structure and function

Andrzejewska, Angelika; Staszak, Klaudia; Kaczmarek-Ryś, Marta; Słomski, Ryszard; Hryhorowicz, Szymon

dc.contributor.author	Andrzejewska, Angelika	en
dc.contributor.author	Staszak, Klaudia	en
dc.contributor.author	Kaczmarek-Ryś, Marta	en
dc.contributor.author	Słomski, Ryszard	en
dc.contributor.author	Hryhorowicz, Szymon	en
dc.date.accessioned	2019-12-03T18:15:12Z
dc.date.available	2019-12-03T18:15:12Z
dc.date.issued	2019-02-01	en
dc.identifier.issn	1730-2366	en
dc.identifier.uri	http://hdl.handle.net/11089/30987
dc.description.abstract	The endocannabinoid system (ECS) consists of the endocannabinoids, cannabinoid receptors and the enzymes that synthesize and degrade endocannabinoids. The whole EC system plays an important role in the proper functioning of the central and autonomic nervous system. ECS is involved in the regulation of the body energy and in the functioning of the endocrine system. It can affect on the regulation of emotional states, motoric movement, operations of the endocrine, immune and digestive system. Many of the effects of cannabinoids are mediated by G coupled –protein receptors: CB1, CB2 and GPR55 but also of transient receptor potential channels (TRPs) which not only induce the sensation of pain but also support inflammation via secretion of pro-inflammatory neuropeptides. In this review work we briefly summarize the role and action of cannabinoid receptors CB1 and CB2, protein-coupled receptor 55 (GPR55) and transient receptor potential vanilloid 1 (TRPV1).	en
dc.publisher	Lodz University Press	en
dc.relation.ispartofseries	Folia Biologica et Oecologica;14	en
dc.rights	This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.	en
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/3.0	en
dc.subject	cannabinoid receptors	en
dc.subject	CB1	en
dc.subject	CB2	en
dc.subject	TRPV1	en
dc.subject	GPR55	en
dc.title	Understanding cannabinoid receptors: structure and function	en
dc.page.number	1-13	en
dc.contributor.authorAffiliation	Institute of Human Genetics, Polish Academy of Sciences, Strzeszynska 32, 60-479 Poznan, Poland	en
dc.contributor.authorAffiliation	Institute of Human Genetics, Polish Academy of Sciences, Strzeszynska 32, 60-479 Poznan, Poland	en
dc.contributor.authorAffiliation	Institute of Human Genetics, Polish Academy of Sciences, Strzeszynska 32, 60-479 Poznan, Poland	en
dc.contributor.authorAffiliation	Institute of Human Genetics, Polish Academy of Sciences, Strzeszynska 32, 60-479 Poznan, Poland	en
dc.contributor.authorAffiliation	Department of Biochemistry and Biotechnology, University of Life Sciences, Dojazd 11, 60-632 Poznan, Poland	en
dc.contributor.authorAffiliation	Institute of Human Genetics, Polish Academy of Sciences, Strzeszynska 32, 60-479 Poznan, Poland	en
dc.identifier.eissn	2083-8484
dc.references	Adam, J.M., Cairins, J., Caulfield, W., Cowley, P., Cumming, I., Easson, M., Edwards, D., Ferguson, M., Goodwin, R., Jeremiah, F. Kiyoi, T., Mistry, A., Moir, E., Morphy, R., Tierney, J., York, M., Baker, J., Cottney, J.E., Houghton, A.K., Westwood, P.J. & Walker, G. 2010. Design, synthesis, and structure–activity relationships of indole-3-carboxamides as novel water soluble cannabinoid CB1 receptor agonists. Medicinal Chemistry Communications, 1: 54–60.	en
dc.references	Albert, P.R. 2011. What is a functional genetic polymorphism? Defining classes of functionality. The Journal of Psychiatry & Neuroscience, 36(6): 363–365. doi: 10.1503/jpn.110137	en
dc.references	Ameri, A. 1999. The effects of cannabinoids on the brain. Progress in Neurobiology, 58(4): 315–348. doi: 10.1016/S0301-0082(98)00087-2	en
dc.references	Befort, K. 2015. Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies. Frontiers in Pharmacology, 5; 6: 6.	en
dc.references	Bisogno, T., Hanus, L., De Petrocellis, L., Tchilibon, S., Ponde, D.E., Brandi, I., Moriello, A.S., Davis, J.B., Mechoulam, R. & Di Marzo V. 2001. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. British Journal of Pharmacology, 134(4): 845–852.	en
dc.references	Brito, R., Sheth, S., Mukherjea, D., Rybak, L.P., Ramkumar, V. 2014. TRPV1: A Potential Drug Target for Treating Various Diseases. Cells, 3(2):517–545.24861977	en
dc.references	Busquets-Garcia, A., Soria-Gomez, E., Bellocchio, L., Marsicano, G. 2016. Cannabinoid receptor type-1: breaking the dogmas. F1000Reseearch, 5, F1000 Faculty Rev-990.	en
dc.references	Cabral, G.A. & Griffin-Thomas, L. 2009. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Reviews in Molecular Medicine, 20, 11:e3.	en
dc.references	Cassano, T., Calcagnini S., Pace, L., De Marco, F., Romano, A., Gaetani, S. 2017. Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target. Frontiers in Neuroscience, 11: 30.	en
dc.references	Clapham, D.E., Julius, D., Montell, C., Schultz, G. 2005. Nomenclature and structure-function relationships of transient receptor potential channels. Pharmacological Reviews, 57(4): 427–450.16382100 doi: 10.1124/pr.57.4.6	en
dc.references	Cui, M., Gosu, V., Basith, S., Hong, S., Choi, S. 2016. Polymodal Transient Receptor Potential Vanilloid Type 1 Nocisensor: Structure, Modulators, and Therapeutic Applications. Advances in Protein Chemistry and Structural Biology, 104: 81–125.	en
dc.references	GeneBank, NCBI. Available from: https://www.ncbi.nlm.nih.gov/gene/7442	en
dc.references	GeneBank, NCBI. Available from: https://www.ncbi.nlm.nih.gov/gene/9290	en
dc.references	GeneCards. Available from: http://www.genecards.org/cgibin/carddisp.pl?gene=CNR2&keywords=cb1	en
dc.references	GeneCards. Available from: http://www.genecards.org/cgibin/carddisp.pl?gene=CNR1&keywords=cb1	en
dc.references	GeneCards. Available from: http://www.genecards.org/cgibin/carddisp.pl?gene=TRPV1	en
dc.references	GeneCards. Available from: http://www.genecards.org/cgibin/carddisp.pl?gene=GPR55&keywords=GPR55	en
dc.references	Gunthorpe, M.J., Szallasi, A. 2008. Peripheral TRPV1 Receptors As Targets for Drug Development: New Molecules and Mechanisms. Current Pharmaceutical Design, 14(1): 32–41.	en
dc.references	Herrera, B., Carracedo, A., Diez-Zaera, M., Gomez del Pulgar, T., Guzman, M., Velasco, G. 2006. The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. Experimental Cell Research, 312(11): 2121–2131.	en
dc.references	Hille, B. 1978. Ionic channels in excitable membranes. Current problems and biophysical approaches. Biophysical Journal, (2): 283–294.656545 doi: 10.1016/S0006-3495(78)85489-7	en
dc.references	Howlett, A.C., Mukhopadhyay, S. 2000. Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chemistry and Physics of Lipids, 108(1–2): 53–70.	en
dc.references	Ishiguro, H., Horiuchi Y., Ishikawa, M., Koga, M., Imai, K., Suzuki, Y., Morikawa, M., Inada, T. Watanabe, Y., Takahashi, M., Someya, T., Ujike, H., Iwata, N., Ozaki, N., Onaivi, E.S., Kunugi, H., Sasaki, T., Itokawa, M., Arai, M., Niizato, K., Iritani, S., Naka, I., Ohashi, J., Kakita, A., Takahashi, H., Nawa, H., Arinami, T. 2010. Brain cannabinoid CB2 receptor in schizophrenia. Biological Psychiatry, 67(10): 974–982.	en
dc.references	Járai, Z, Wagner, J.A., Varga, K., Lake, K.D., Compton, D.R., Martin, B.R., Zimmer, A.M., Bonner, T.I., Buckley, N.E., Mezey, E., Razdan, R.K., Zimmer, A., Kunos, G. 1999. “Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proceedings of the National Academy of Sciences of the United States of America, 96 (24): 14136–41 doi: 10.1073/pnas.96.24.14136	en
dc.references	Johns, D.G., Behm, D.J., Walker, D.J., Ao, Z., Shapland, E.M., Daniels, D.A., Riddick, M., Dowel,l S., Staton, P.C., Green, P., Shabon, U., Bao, W., Aiyar, N., Yue, T.L., Brown, A.J., Morrison, A.D., Douglas, S.A. 2007. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. British Journal of Pharmacology, 152 (5): 825–31	en
dc.references	Kazula, A. 2009. Zastosowanie naturalnych kannabinoidów i endokannabinoidów w terapii. Postępy farmakoterapii, 65(2): 147–160.	en
dc.references	Komorowski, J., Stępień, H. 2007. Rola układu endokannabinoidowego w regulacji czynności dokrewnej i kontroli równowagi energetycznej człowieka. Postępy Higieny Medycyny Doświadczalnej, 61: 99–105.	en
dc.references	Konarska, L., Ellert, A. 2004. Receptory kannabinoidowe. In: Nowak, J.Z., Zawilska, J.B. (eds). Receptory i mechanizmy przekazywania sygnału. Wydawnictwo Naukowe PWN, pp. 464–490.	en
dc.references	Karjnik M., Żylicz Z. 2003. Kannabinoidy w medycynie paliatywnej. Polska Medycyna Paliatywna, 2: 123–131.	en
dc.references	Laprairie, R.B., Kelly, M.E., Denovan-Wright, E.M. 2012. The dynamic nature of type 1 cannabinoid receptor (CB1) gene transcription. British Journal of Pharmacology, 167(8): 1583–1595.	en
dc.references	Lauckner, J.E., Jensen, J.B., Chen, H.Y., Lu, H.C., Hille, B., Mackie, K. 2008. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proceedings of the National Academy of Sciences of the United States of America, 105: 2699–2704.	en
dc.references	Lee, Y., Hong, S., Cui, M., Sharma, P.K., Lee, J., Choi, S. 2015. Transient receptor potential vanilloid type 1 antagonists: a patent review (2011-2014). Expert Opinion on Therapeutic Patents, 25(3): 291–318.	en
dc.references	Liao, M., Cao, E., Julius, D., Cheng Y. 2013. Structure of the TRPV1 ion channel determined by electron cryo-microscopy. Nature, 504: 107–112.	en
dc.references	Lishko, P.V., Procko, E., Jin, X., Phelps, C.B., Gaudet R. 2007. The Ankyrin Repeats of TRPV1 Bind Multiple Ligands and Modulate Channel Sensitivity. Neuron, 54: 905–918.	en
dc.references	Mackie, K., Stella, N. 2006. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS Journal, 8(2): E298–306. doi: 10.1007/BF02854900	en
dc.references	Martínez, N., Abán, C.E., Leguizamón, G.F., Damiano, A.E., Farina, M.G. 2016. TPRV-1 expression in human preeclamptic placenta. Placenta, 40: 25–28. doi: 10.1016/j.placenta.2016.02.008	en
dc.references	McHugh, D., Tanner, C., Mechoulam, R., Pertwee, R.G., Ross, R.A., 2008. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. Molecular Pharmacology, 73 (2): 441–50.	en
dc.references	McKallip, R.J., Lombard, C., Fisher, M., Martin, B.R., Ryu, S., Grant, S., Nagarkatti, P.S., Nagarkatti M. 2002. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood, 100(2): 627–634.12091357 doi: 10.1182/blood-2002-01-0098	en
dc.references	Navarrete, F.., Rodríguez-Arias, M., Martín-García, E., Navarro, D., García-Gutiérrez, M.S., Aguilar, M.A., Aracil-Fernández, A., Berbel, P., Miñarro, J., Maldonado, R., Manzanares, J. 2013. Role of CB2 cannabinoid receptors in the rewarding, reinforcing, and physical effects of nicotine. Neuropsychopharmacology, 38(12): 2515–2524. doi: 10.1038/npp.2013.157	en
dc.references	Nicoll, G., Davidson, S., Shanley, L., Hing, B., Lear, M., McGuffin, P., Ross, R., MacKenzie, A. 2012. Allele-specific differences in activity of a novel cannabinoid receptor 1 (CNR1) gene intronic enhancer in hypothalamus, dorsal root ganglia, and hippocampus. The Journal of Biological Chemistry, 287(16): 12828–12834.	en
dc.references	Nilius, B., Owsianik, G. 2011. The transient receptor potential family of ion channels. Genome Biology, 12(3): 218.0.21401968	en
dc.references	Numazaki, M., Tominaga, T., Takeuchi, K., Murayama, N., Toyooka, H., Tominaga, M. 2003. Structural determinant of TRPV1 desensitization interacts with calmodulin. Proceedings of the National Academy of Sciences of the United States of America, 100(13):8002–8006.	en
dc.references	Pawlak, M., Łaczmański, Ł., Milewicz, A. 2011. Rola układu endokannabinoidowego i polimorfizmów genu CNR1 w powstawaniu otyłości. Endokrynologia, Otyłość i Zaburzenia Przemiany Materii, 7(3): 192–196.	en
dc.references	Pertwee, R.G. 2006. Cannabinoid pharmacology: the first 66 years. British Journal of Pharmacology, 147: 163–171.	en
dc.references	Pertwee, R.G. 2009. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. British Journal of Pharmacology, 156(3): 397–411.	en
dc.references	Pietrzak, B., Dunaj, A., Piątkowska, K. 2011. Rola układu kannabinoidowego w patogenezie oraz poszukiwaniu nowych możliwości farmakoterapii zespołu zależności alkoholowej. Postępy Higieny Medycyny Doświadczalnej, 65: 606–615.	en
dc.references	Racz, I., Nadal, X., Alferink, J., Baños, J.E., Rehnelt, J., Martín, M., Pintado, B., Gutierrez-Adan, A., Sanguino, E., Manzanares, J., Zimmer, A., Maldonado, R. 2008. Crucial Role of CB2 cannabinoid receptor in the regulation of central immune responses during neuropathic pain. Journal of Neuroscience, 28(46): 12125–12135.	en
dc.references	Rutkowska, M., Jamontt, J. 2005. Rola układu kannabinoidowego w fizjologii i patofizjologii ośrodkowego układu nerwowego. Advances in Clinical and Experimental Medicine, 14(6): 1243–1252.	en
dc.references	Ryberg, E., Vu, H.K., Larsson, N., Groblewski, T., Hjorth, S., Elebring, T., Sjögren, S., Greasley, P.J. 2005. Identification and characterisation of novel splice variant of the human CB1 receptor. FEBS Letters, 579(1): 259–264.	en
dc.references	Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N.O., Leonova, J., Elebring, T., Nilsson, K., Drmota, T. & Greasley, P.J. 2007. The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology, 152(7): 1092–1101.	en
dc.references	Sawzdargo, M., Nguyen, T., Lee, D.K., Lynch, K.R., Cheng, R., Heng, H.H., George, S.R., O’Dowd, B.F. 1999. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain research. Molecular brain research, 64(2): 193–198. doi: 10.1016/S0169-328X(98)00277-0	en
dc.references	Shire, D., Carillon, C., Kaghad, M., Calandra, B., Rinaldi-Carmona, M., Le Fur, G., Caput, D., Ferrara, P. 1995. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. The Journal of Biological Chemistry, 270(3): 3726–3731.	en
dc.references	Shore, D.M., Reggio, P.H. 2015. The therapeutic potential of orphan GPCRs, GPR35 and GPR55. Frontiers in Pharmacology, 6: 69.	en
dc.references	Simcocks, A.C., O’keefe, L., Jenkin, K.A., Mathai, M.L., Hryciw, D.H., Mcainch, A.J. 2014. A potential role for GPR55 in the regulation of energy homeostasis. Drug Discovery Today, 19:1145–1151.24370891 doi: 10.1016/j.drudis.2013.12.005	en
dc.references	Staruschenko, A., Jeske, N.A., Akopian, A.N. 2010. Contribution of TRPV1-TRPA1 Interaction to the Single Channel Properties of the TRPA1 Channel. The Journal of Biological Chemistry, 285: 15167–15177.	en
dc.references	Sullivan, J.M. 2000. Cellular and molecular mechanisms underlying learning and memory imrairments produced by cannabinoids. Learning & Memory, 7(3): 132–139.10837502	en
dc.references	Szallasi, A., Cortright, D.N., Blum, C.A., Eid, S.R. 2007, The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nature Reviews Drug Discovery, 6: 357–372.	en
dc.references	Tilley, D.G. 2011. G protein-dependent and G protein-independent signaling pathways and their impact on cardiac function. Circulation Research, 109(2): 217–230.	en
dc.references	U.S. National Institutes of Health, 2013. https://clinicaltrials.gov	en
dc.references	Zhang, H.Y., Gao, M., Liu, Q.R., Bi, G.H., Li, X., Yang, H.J., Gardner, E.L., Wu, J., Xi, Z.X. 2014. Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proceedings of the National Academy of Sciences of the United States of America, 111(46): E5007–15.	en
dc.references	Zoratti, C., Kipmen-Korgun, D., Osibow, K., Malli, R., Graier, W.F. 2003. Anandamide initiates Ca(2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells. British Journal of Pharmacology, 140(8): 1351–1362.	en
dc.references	Zygmunt, P.M., Petersson, J., Andersson, D.A., Chuang, H.H., Sørgård, M., Di Marzo, V., Julius, D., Högestätt, E.D. 1999. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature, 400: 452–457.	en
dc.contributor.authorEmail	szymon.hryhorowicz@igcz.poznan.pl	en
dc.identifier.doi	10.1515/fobio-2017-0004	en

Pliki tej pozycji

Nazwa:: fobio-2017-0004.pdf
Rozmiar:: 610.8KB
Format:: PDF

Oglądaj/Otwórz

Pozycja umieszczona jest w następujących kolekcjach

Acta Universitatis Lodziensis. Folia Biologica et Oecologica 14/2018 [5]

Pokaż uproszczony rekord

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Poza zaznaczonymi wyjątkami, licencja tej pozycji opisana jest jako This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.